Merck KGaA, Darmstadt, Germany Partners with Veeva to Transform Medical Information Operations Globally

Merck KGaA, Darmstadt, Germany Partners with Veeva to Transform Medical Information Operations Globally In a groundbreaking move, Merck KGaA, Darmstadt, Germany has joined forces with Veeva Systems to revolutionize its global medical information operations. This strategic partnership will see the implementation of Veeva Vault MedInquiry as Merck KGaA's worldwide medical information management sy..

  • format_list_bulleted BS
  • · 2023. 7. 13.
  • textsms

Merck Finalizes $10.8B Prometheus Buy

Merck has finalized its acquisition of Prometheus Biosciences for $10.8 billion, gaining five candidates for inflammatory bowel and immune-mediated diseases, including the leading candidate MK-7240 for ulcerative colitis and Crohn's disease. The purchase marks Merck's further expansion into the immunology space. The all-cash agreement includes buying all outstanding shares of Prometheus at a 75%..

  • format_list_bulleted BS
  • · 2023. 6. 20.
  • textsms

Merck Completes Acquisition of Prometheus Biosciences, Inc.

Merck & Co has acquired Prometheus Biosciences, Inc. for $10.8 billion, making it a wholly-owned subsidiary and helping Merck expand its presence in immunology while strengthening its pipeline with a potential best-in-class candidate for immune-mediated diseases such as ulcerative colitis and Crohn’s disease. The leading clinical candidate, PRA-023, is now known as MK-7240 and is a humanized mon..

  • format_list_bulleted BS
  • · 2023. 6. 19.
  • textsms

Merck Eyes Keytruda Indication Update with Phase III Gastric Cancer Data

Merck has announced that its blockbuster drug Keytruda met one of its primary endpoints in a Phase III trial for patients with esophageal cancer. The results are an important step toward full approval of the drug for this indication. Merck is now working with the FDA to update the current indication for Keytruda "to those patients whose tumors are PD-L1 positive" following positive results from ..

  • format_list_bulleted BS
  • · 2023. 6. 19.
  • textsms

Biopharma Confronts a Rising Tide of Ransomware Attacks

Biopharma companies are increasingly becoming targets of ransomware attacks, with the number of breaches rising during the COVID-19 pandemic. Japanese company Eisai recently announced that it was hit by a ransomware attack, joining other pharmaceutical companies like Sun Pharmaceuticals, Novartis and AstraZeneca. According to Constella Intelligence, for the top 20 pharma companies, the total num..

  • format_list_bulleted BS
  • · 2023. 6. 15.
  • textsms

Merck Gets FDA Fast Track for Efinopegdutide, Previews NASH Data Versus Novo’s Semaglutide

Merck's efinopegdutide has received FDA Fast Track designation for the treatment of non-alcoholic steatohepatitis (NASH), and Merck has released Phase IIa study results comparing efinopegdutide to Novo Nordisk's semaglutide. The new NAFLD data will be presented at the upcoming European Association for the Study of the Liver annual congress, and Merck plans to use both this data and the Fast Trac..

  • format_list_bulleted BS
  • · 2023. 6. 15.
  • textsms

Valneva Reports Strong Phase III Chikungunya Vaccine Data After Merck’s Exit from Race

French company Valneva has released positive results from a Phase III study of its chikungunya vaccine candidate VLA1553, following Merck's exit from the race earlier this year. The vaccine showed a 28-day seroprotection rate of 98.9% in participants given the inoculation, according to results published in medical journal The Lancet. However, more than half of those vaccinated developed at least..

  • format_list_bulleted BS
  • · 2023. 6. 14.
  • textsms

Chamber of Commerce Files IRA Lawsuit Against Biden Administration, Follows Merck

The U.S. Chamber of Commerce has filed a lawsuit against the Department of Health and Human Services and Centers for Medicare & Medicaid Services in federal court, challenging the constitutionality of the Inflation Reduction Act’s drug price negotiation program. The lawsuit claims that the IRA violates the Constitution's "requirements of limited government, property rights, the rule of law, and ..

  • format_list_bulleted BS
  • · 2023. 6. 13.
  • textsms

ASCO in Review: Oncologists See Practice-Changing, Affirming Data

The American Society of Clinical Oncology (ASCO) conference showcased exciting new data for oncology treatments, with several drugs showing significant success rates. AstraZeneca's Tagrisso was found to outperform a placebo in trials for EGFR-mutated non-small cell lung cancer, Novartis' Kisqali impressed researchers with its ability to treat early breast cancer, and Merck's Keytruda was more ef..

  • format_list_bulleted BS
  • · 2023. 6. 9.
  • textsms